The antiphospholipid syndrome (APS) is a disease discovered just 25 years ago. Although clinical manifestations have been clearly described, pathogenetic mechanisms are still barely understood. A recent hypothesis involves inflammation in the setting of APS morbidity and experimental data support the activation of complement cascade as a pivotal event in its physiopathology. In this review we will analyze the recent literature, focusing on contemporary and emerging aspects of complement-mediated disease pathogenesis and we will point up the clinical significance of this novel finding
Obstetric complications are the hallmark of antiphospholipid syndrome. Recurrent miscarriage, early ...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic ev...
The anti-phospholipid syndrome (APS) is characterized by recurrent fetal loss, vascular thrombosis a...
Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the ...
Anti-phospholipid syndrome (APS) is defined by recurrent arterial/venous thrombosis and/or fetal los...
Objective. During the last decade, the role of complement system activation in the pathogenesis of a...
Pregnancy represents a physiologic condition where maternal immune system tolerates the semi-allogen...
Antiphospholipid syndrome (APS) is defined by recurrent pregnancy loss and thrombosis in the presenc...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic ev...
OBJECTIVE: To evaluate the association between serum complement levels (C3 and C4) and obstetric com...
The association between antiphospholipid antibodies (aPL) and thrombophilic state in antiphospholipi...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Evidence about the relevance of the complement system, a highly conserved constituent of the innate ...
Obstetric complications are the hallmark of antiphospholipid syndrome. Recurrent miscarriage, early ...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic ev...
The anti-phospholipid syndrome (APS) is characterized by recurrent fetal loss, vascular thrombosis a...
Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the ...
Anti-phospholipid syndrome (APS) is defined by recurrent arterial/venous thrombosis and/or fetal los...
Objective. During the last decade, the role of complement system activation in the pathogenesis of a...
Pregnancy represents a physiologic condition where maternal immune system tolerates the semi-allogen...
Antiphospholipid syndrome (APS) is defined by recurrent pregnancy loss and thrombosis in the presenc...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic ev...
OBJECTIVE: To evaluate the association between serum complement levels (C3 and C4) and obstetric com...
The association between antiphospholipid antibodies (aPL) and thrombophilic state in antiphospholipi...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Evidence about the relevance of the complement system, a highly conserved constituent of the innate ...
Obstetric complications are the hallmark of antiphospholipid syndrome. Recurrent miscarriage, early ...
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic ev...